drugset / Trial / NCT04699123
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Phase 2
Active not recruiting
159 enrolled
Yale University
Merck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collabNextCure, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
Timeline
- Start
- 2021-02-04
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NC318 | Monoclonal antibody | 400 mg | Intravenous |
| Subject | NC318 | Monoclonal antibody | 800 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |